The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load

Journal of Infection

Volumn 36, Issue 3, 1998, Pages 307-311

  Soriano, V ^a,c   Castilla, J ^b   Gomez Cano M ^a   Holguin A ^a   Villalba, N ^a   Mas, A ^a   Gonzalez Lahoz J ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b CARLOS III INSTITUTE OF HEALTH   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN;

ANALYTICAL PARAMETERS; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNIZATION; IMMUNOGENICITY; INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; ONSET AGE; PHENOTYPE; SEROCONVERSION; STATISTICAL MODEL; SYNCYTIUM; T LYMPHOCYTE; VIREMIA; VIRUS LOAD; VIRUS MORPHOLOGY;

EID: 0031813397     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(98)94351-1     Document Type: Article

References (40)

1. Wei X, Ghosh S, Taylor M et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-122.
2. Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126.
3. Coffin J. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995; 267: 483-489.
4. Perelson A, Neumann A, Markowitz M, Leonard J, Ho D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-1586.
5. Feinberg M. Changing the natural history of HIV disease. Lancet 1996; 348: 239-246.
6. Havlir D, Richman D. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996; 124: 984-994.
7. Phillips A, Eron J, Bartlett J et al, HIV-1 RNA levels and the development of clinical disease. AIDS 1996; 10: 859-865.
8. Mellors J, Rinaldo C, Gupta P, White R, Todd J, Kingsley L. Prognosis in HIV infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-1170.
9. Saag M, Holodniy M, Kuritzkes D. HIV viral load markers in clinical practice. Nature Med 1996; 2: 625-629.
10. Carpenter C, Fischl M, Hammer S et al. Antiretroviral therapy for HIV infection in 1996. JAMA 1996; 276: 146-154.
11. Mellors J, Kingsley L, Rinaldo C et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-579.
12. Jurriaans S, Van Gemen B, Weverling G et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of viral course? Virology 1994; 204: 223-233.
13. Henrard D, Phillips J, Muenz L et al. Natural history of HIV-1 cell-free viremia. JAMA 1995; 274: 554-558.
14. O'Brien T, Blattner W, Waters D et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996; 276: 105-110.
15. Mellors J. Viral load and clinical outcome: a review of recent studies. International Workshop on HIV Drug resistance. Whistler 1996. Antiviral Therapy 1996: 1 (Suppl. 1): 21-22.
16. 6/I. AIDS 1997; 11: 53-57.
17. Coffin J. HIV viral dynamics. AIDS 1996; 10 (Suppl. 3): 75-84.
18. Carré N, Deveau C, Belanger F et al. Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients. AIDS 1994; 8: 797-802.
19. Rosenberg P, Goedert J, Biggar R et al. Effect of age at seroconversion on the natural AIDS incubation distribution. AIDS 1994; 8: 804-810.
20. Tumbarello M, Tacconelli E, Cauda R, Ortona L. Age as a prognostic factor in AIDS. Lancet 1996; 348: 623-624.
21. Darby S, Ewart D, Giangrande P, Spooner R, Rizza C. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996; 347: 573-579.
22. Vandamme A, Schmit J, Van Dooren S et al. Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV Monitor test. J AIDS Hum Retrovirol 1996; 13: 127-139.
23. Maini M, Gilson R, Chavda N et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med 1996; 72: 27-31.
24. Bryant J, Wylie B, Yuan F, Ribeiro A, Thompson A, Cooley M, Fletcher A. Effect of blood donation on the establishment of normal ranges of lymphocyte subsets. Transfusion 1996; 36: 559-566.
25. Ioannidis J, Cappelleri J, Lau J, Sacks H, Skolnik P. Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection: a mathematical model. AIDS 1996; 10: 255-262.
26. Katzenstein D, Hammer S, Hughes M et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1091-1098.
27. Katzenstein T, Pedersen C, Nielsen C, Lundgren J, Jakobsen P, Gerstot J. Longitudinal serum HIV-RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996; 10: 167-173.
28. Bourinbaiar A. The ratio of defective HIV-1 particles to replication-competent infectious virions. Acta Virol 1994; 38: 59-61.
29. Heneine W, Yamamoto S, Switzer W, Spira T, Folks T. Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with HIV type 1. J Infect Dis 1995; 171: 1210-1216.
30. Boni J, Pyra H, Schupbach J. Sensitive detection and quantification of particle-associated RT in plasma of HIV-1 infected individuals by the product-enhanced reverse transcriptase (PERT) assay. J Med Virol 1996; 49: 23-28.
31. Yamamoto S, Folks T, Heneine W. Highly sensitive qualitative and quantitative detection of RT activity: optimization, validation, and comparative analysis with other detection systems. J Virol Methods 1996; 61: 135-143.
32. th Conference on Retroviruses and Opportunistic Infections, Washington, 1997.
33. Brettle R, McNeil A, Burns S et al. Progression of HIV: follow-up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983-1985. AIDS 1996; 10: 419-430.
34. Kaslow R, Carrington M, Apple R et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2: 405-411.
35. Malkovsky M. HLA and natural history of HIV infection. Lancet 1996; 348: 142-143.
36. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273: 1856-1861.
37. Fauci A. Host factors and the pathogenesis of HIV-induced disease. Nature 1996; 384: 529-534.
38. Pantaleo G, Demarest J, Schacker T et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997; 94: 254-258.
39. Piatak M, Saag M, Yang L et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259: 1749-1754.
40. Soriano V, Gómez-Cano M, Castilla J et al. Relationship between the duration of HIV infection, viral load, and CD4 + lymphocyte counts. Med Clin (Barc) 1998 (in press).